Top

Published in:

Open Access 17-08-2024 | Glucose Monitoring and Insulin Delivery Devices | Review

Effectiveness, safety, and preference of transdermal insulin compared to subcutaneous insulin in the treatment of diabetes patients: a systematic review of clinical trials

Authors: Liknaw Workie Limenh, Nigus Kassie Worku, Mihret Melese, Dereje Esubalew, Eneyew Talie Fenta, Mickiale Hailu, Alemwork Abie, Molla Getie Mehari, Tenagnework Eseyneh Dagnaw, Amare Mebrat Delie

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Abstract

Background

Several studies were performed on transdermal (TD) insulin delivery in vitro and in vivo, and recently, the study groups included a clinical trial in humans. Therefore, this systematic review was conducted to get summary information about the effectiveness, safety, and preferability of TD insulin in comparison with subcutaneous insulin delivery.

Methods

We conducted a thorough search to find studies in the databases Cochrane Library, MEDLINE via PubMed, Web of Science Core Collection, EMBASE, Scopus, Hinari, Medlib, and Magiran until January 2024. We included 18 randomized clinical trials.

Results

Although there are various types of TD delivery methods, the TD insulin delivery methods that have undergone clinical trials are the TD patch, micro needle TD insulin delivery, and TD insulin jet injector. Eighteen studies were conducted on TD insulin delivery, which showed either superior or comparable effectiveness, safety, and preferability of TD insulin in comparison with SC insulin. About eleven out of eighteen studies (61.1%) showed more effective blood glucose control than SC delivery, and the remaining seven studies showed comparable effectiveness with SC delivery. Eleven studies (61.1%) showed equal tolerability of TD insulin versus SC insulin, and seven studies (38.9%) showed more tolerability of TD insulin over SC insulin. In most studies, eleven out of eighteen (61.1%) showed a higher preference for TD insulin delivery over traditional SC delivery; sixth out of eighteen (33.3%) showed equal preferability for TD insulin versus SC insulin; and only one study (5.6%) showed that TD insulin delivery was less preferable than SC insulin.

Conclusion

The review revealed that clinical trials have demonstrated the effectiveness of TD insulin delivery methods such as TD patches, MN-based insulin delivery, and insulin jet injectors compared to traditional SC routes of administration. The studies showed the superior or comparable effectiveness of TD insulin in controlling blood glucose levels. Additionally, TD insulin delivery was found to be equally or more tolerable than SC insulin delivery in all studies. Overall, the majority of studies favored TD insulin delivery over traditional SC delivery methods, highlighting its potential as a preferred option for insulin administration.

Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z. Advances in transdermal insulin delivery. Adv Drug Deliv Rev. 2019;139:51–70.PubMedCrossRef

Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov. 2015;14(1):45–57.PubMedCrossRef

Afsaneh E, Sharifdini A, Ghazzaghi H, Ghobadi MZ. Recent applications of machine learning and deep learning models in the prediction, diagnosis, and management of diabetes: a comprehensive review. Diabetes Metab Syndr. 2022;14(1):1–39.

Hoyer A, Brinks R, Tönnies T, Saydah SH, D’Agostino RB Jr, Divers J, Isom S, Dabelea D, Lawrence JM, Mayer-Davis EJ, Pihoker C. Estimating incidence of type 1 and type 2 diabetes using prevalence data: the SEARCH for diabetes in Youth study. BMC Med Res Methodol. 2023;23(39):1–8.

Hu S, Su X, Fan G. Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis. Diabetes Metab Syndr. 2023;15(218):1–11.

Wang XM, Zhong SP, Li GF, Zhuge FY. Diabetes duration or age at onset and mortality in insulin-dependent diabetics: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;15(147):1–10.

Nordquist L, Roxhed N, Griss P, Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm Res. 2007;24:1381–8.PubMedCrossRef

Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(8):502–14.PubMedPubMedCentralCrossRef

Olorunsola EO, Udoh IE, Ekott MB, Alozie MF, Davies KG. Biopharmaceutics and clinical outcomes of emerging dosage forms of insulin: a systematic review. Diabet Epidemiol Manag. 2023;9:1–7.CrossRef

10.

Qiu Y, Qin G, Zhang S, Wu Y, Xu B, Gao Y. Novel lyophilized hydrogel patches for convenient and effective administration of microneedle-mediated insulin delivery. Int J Pharm. 2012;437(1–2):51–6.PubMedCrossRef

11.

Kang SL, Hwang YN, Kwon JY, Kim SM. Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis. Diabetes Metab Syndr. 2022;14(187):1–12.

12.

Godoi A, Reis Marques I, Padrão EM, Mahesh A, Hespanhol LC, Riceto Loyola Júnior JE, de Souza IA, Moreira VC, Silva CH, Miyawaki IA, Oommen C. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials. Diabetes Metab Syndr. 2023;15(190):1–18.

13.

Heise T. The future of insulin therapy. Diabetes Res Clin Pract. 2021;175:1–10.CrossRef

14.

Cheung KK, Senior PA. Novel and emerging insulin preparations for type 2 diabetes. Can J Diabetes. 2015;39:S160–6.PubMedCrossRef

15.

Sugumar V, Ang KP, Alshanon AF, Sethi G, Yong PV, Looi CY, Wong WF. A comprehensive review of the evolution of insulin development and its delivery method. Pharmaceutics. 2022;14(7):1–28.CrossRef

16.

Hussain M, Hafeez A, Kushwaha SP. Nanoformulation mediated transdermal delivery of anti-diabetic drugs: an updated review. Intell Pharm. 2023;1(4):192–200.

17.

Roy L, Bhattacharjee M. Overview of novel routes of insulin: current status. Int J Adv Med. 2020;7(10):1597–602.CrossRef

18.

Sibiya N, Mbatha B, Ngubane P, Khathi A. Celebrating a century of insulin Discovery: a critical Appraisal of the emerging alternative insulin Delivery systems. Curr Drug Deliv. 2023;20(6):656–68.PubMedCrossRef

19.

Verma A, Kumar N, Malviya R, Sharma PK. Emerging trends in noninvasive insulin delivery. J Pharm. 2014; 1–10.

20.

Limenh LW. A review on oral novel delivery systems of insulin through the novel delivery system formulations: a review. SAGE Open Med. 2024;12:1–11.CrossRef

21.

Zhao J, Xu G, Yao X, Zhou H, Lyu B, Pei S, Wen P. Microneedle-based insulin transdermal delivery system: current status and translation challenges. Drug Deliv Transl Res. 2022;12(10):2403–27.PubMedCrossRef

22.

Sugumar V, Hayyan M, Madhavan P, Wong WF, Looi CY. Current development of chemical penetration enhancers for transdermal insulin delivery. Biomedicines. 2023;11(664):1–25.

23.

Iliopoulos F, Sil BC, Evans CL. The role of excipients in promoting topical and transdermal delivery: current limitations and future perspectives. Front Drug Deliv. 2022;2:1049848.CrossRef

24.

Limenh LW. Advances in the transdermal delivery of antiretroviral drugs. SAGE Open Med. 2024;12:1–9.CrossRef

25.

Kumar R, Philip A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. TJPR. 2007;6(1):633–44.

26.

Li YZ, Quan YS, Zang L, Jin MN, Kamiyama F, Katsumi H, Yamamoto A, Tsutsumi S. Transdermal delivery of insulin using trypsin as a biochemical enhancer. Biol Pharm Bull. 2008;31(8):1574–9.PubMedCrossRef

27.

Sadeqi A, Kiaee G, Zeng W, Rezaei Nejad H, Sonkusale S. Hard polymeric porous microneedles on stretchable substrate for transdermal drug delivery. Sci Rep. 2022;12(1):1–10.CrossRef

28.

Nguyen HX, Nguyen CN. Microneedle-mediated transdermal delivery of biopharmaceuticals. Pharmaceutics. 2023;15(277):1–35.

29.

Lai-Cheong JE, McGrath JA. Structure and function of skin, hair and nails. Medicine. 2013;41(6):317–20.CrossRef

30.

Matteucci E, Giampietro O, Covolan V, Giustarini D, Fanti P, Rossi R. Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des Devel Ther. 2015;9:3109–18.PubMedPubMedCentralCrossRef

31.

Hofmann E, Schwarz A, Fink J, Kamolz LP, Kotzbeck P. Modelling the complexity of human skin in vitro. Biomedicines. 2023;11(794):1–17.

32.

Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control. 2006;34(10):S98–110.CrossRef

33.

Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6):269–80.PubMedCrossRef

34.

Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: a review. Biomater Res. 2021;25(24):1–15.

35.

Avcil M, Çelik A. Microneedles in Drug Delivery: Progress and challenges. Micromachines. 2021;12(1321):1–15.

36.

Andrews S, Lee JW, Choi SO, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. Pharm Res. 2011;28:2110–8.PubMedPubMedCentralCrossRef

37.

Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.PubMedPubMedCentralCrossRef

38.

Zhang N, Zhou X, Xie H, Yang Z. Dissolving polymer microneedles for transdermal delivery of insulin. Front Pharmacol. 2021;12:1–10.

39.

Ahad A, Raish M, Bin Jardan YA, Al-Mohizea AM, Al-Jenoobi FI. Delivery of insulin via skin route for the management of diabetes mellitus: approaches for breaching the obstacles. Pharmaceutics. 2021;13(1):1–17.CrossRef

40.

Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, Dua K. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother. 2019;109:1249–58.PubMedCrossRef

41.

He X, Sun J, Zhuang J, Xu H, Liu Y, Wu D. Microneedle system for transdermal drug and vaccine delivery: devices, safety, and prospects. Dose-Response. 2019;17(4):1–18.CrossRef

42.

Mdanda S, Ubanako P, Kondiah PP, Kumar P, Choonara YE. Recent advances in microneedle platforms for transdermal drug delivery technologies. Polymers. 2021;13(2405):1–24.

43.

Wong WF, Ang KP, Sethi G, Looi CY. Recent advancement of medical patch for transdermal drug delivery. Medicina. 2023;59(778 4):1–20.

44.

Trimzi MA, Ham YB. A needle-free jet injection system for controlled release and repeated Biopharmaceutical Delivery. Pharmaceutics. 2021;13(1770):1–25.

45.

Cohen Y, Cohen G, Tworowski D, Eretz-Kdosha N, Silberstein E, Fallik E, Poverenov E. Biocompatible nanocarriers for passive transdermal delivery of insulin based on self-adjusting N-alkylamidated carboxymethyl cellulose polysaccharides. Nanoscale Adv. 2022;4(9):2124–33.PubMedPubMedCentralCrossRef

46.

Bergenstal RM, Johnson ML, Aroda VR, Brazg RL, Dreon DM, Frias JP, Kruger DF, Molitch ME, Mullen DM, Peyrot M, Richter S. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167–73.PubMedCrossRef

47.

Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molitch M, Raskin P, Remtema H, Strowig S, Whitehouse F. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. Diabetes Technol Ther. 2011;13(10):1031–7.PubMedPubMedCentralCrossRef

48.

Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther. 2011;13(4):443–50.PubMedCrossRef

49.

Gupta J, Felner EI, Prausnitz MR. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther. 2009;11(6):329–37.PubMedPubMedCentralCrossRef

50.

Norman JJ, Brown MR, Raviele NA, Prausnitz MR, Felner EI. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14(6):459–65.PubMedCrossRef

51.

Rini CJ, McVey E, Sutter D, Keith S, Kurth HJ, Nosek L, Kapitza C, Rebrin K, Hirsch L, Pettis RJ. Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear. Drug Deliv Transl Res. 2015;5:332–45.PubMedPubMedCentralCrossRef

52.

Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther. 2011;13(4):451–6.PubMedPubMedCentralCrossRef

53.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther. 2011;13(4):435–42.PubMedCrossRef

54.

McVey E, Hirsch L, Sutter DE, Kapitza C, Dellweg S, Clair J, Rebrin K, Judge K, Pettis RJ. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol. 2012;6(4):743–54.PubMedPubMedCentralCrossRef

55.

Kochba E, Levin Y, Raz I, Cahn A. Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2016;18(9):525–31.PubMedPubMedCentralCrossRef

56.

Ji L, Gao L, Chen L, Wang Y, Ma Z, Ran X, Sun Z, Xu X, Wang G, Guo L, Shan Z. Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: a 16-week, multicenter, randomized clinical trial (the FREE study). EClinicalMedicine. 2020;23:1–8.CrossRef

57.

Jin X, Han J, Guan Q, Zhang X. A clinical observation study on the effect of needle-free insulin syringe on blood glucose control and well-being index in patients with early-onset type 2 diabetes mellitus. Front Endocrinol. 2023;14:01–7.CrossRef

58.

Xing Y, Xie X, Xu J, Liu J, He Q, Yang W, Zhang N, Li X, Wang L, Fu J, Zhou J. Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study. Expert Opin Drug Deliv. 2019;16(9):995–1002.PubMedCrossRef

59.

Wu Q, Deng M, Wang W, Pan Q, Guo L. A self-controlled, cross-over study of intensive insulin treatment with needle-based injection versus needle-free injection in hospitalized patients with type 2 diabetes. Front Endocrinol. 2023;14:1162176.CrossRef

60.

Guo L, Xiao X, Sun X, Qi C. Comparison of jet injector and insulin pen in controlling plasma glucose and insulin concentrations in type 2 diabetic patients. Medicine. 2017;96(1):1–5.CrossRef

61.

Reutens AT, Balkau B, Cohen N. A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection. Diabetes Technol Ther. 2014;16(4):235–40.PubMedCrossRef

62.

De Wit HM, Engwerda EE, Tack CJ, De Galan BE. Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. Diabetes Obes Metab. 2015;17(11):1093–9.PubMedCrossRef

63.

Engwerda EE, Tack CJ, De Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. Diabetes Care. 2013;36(11):3436–41.PubMedPubMedCentralCrossRef

64.

Barolet D, Benohanian A. Current trends in needle-free jet injection: an update. Clin Cosmet Investig Dermatol. 2018;11:231–8.PubMedPubMedCentralCrossRef

65.

Ng LC, Gupta M. Transdermal drug delivery systems in diabetes management: a review. Asian J Pharm Sci. 2020;15(1):13–25.PubMedCrossRef

66.

Wang PM, Cornwell M, Prausnitz MR. Minimally invasive extraction of dermal interstitial fluid for glucose monitoring using microneedles. Diabetes Technol Ther. 2005;7:131–41.PubMedCrossRef

Title: Effectiveness, safety, and preference of transdermal insulin compared to subcutaneous insulin in the treatment of diabetes patients: a systematic review of clinical trials
Authors: Liknaw Workie Limenh
Nigus Kassie Worku
Mihret Melese
Dereje Esubalew
Eneyew Talie Fenta
Mickiale Hailu
Alemwork Abie
Molla Getie Mehari
Tenagnework Eseyneh Dagnaw
Amare Mebrat Delie
Publication date: 17-08-2024
Publisher: BioMed Central
Keywords: Glucose Monitoring and Insulin Delivery Devices
Insulins
Type 1 Diabetes
Type 2 Diabetes
Diabetes
Metabolic Disease and Nutrition
Published in: Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-024-01442-5

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

EASD 2024

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

A nonlinear relationship between the triglycerides to high-density lipoprotein cholesterol ratio and stroke risk: an analysis based on data from the China Health and Retirement Longitudinal Study

The association of changes in the Chinese visceral adiposity index and cardiometabolic diseases: a cohort study

The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis

Comparison of atherogenic indices for predicting the risk of metabolic syndrome in Southwest Iran: results from the Hoveyzeh Cohort Study (HCS)

Increased serum asprosin is correlated with diabetes mellitus-induced erectile dysfunction

Sex differences in the association between metabolic score for insulin resistance and the reversion to normoglycemia in adults with prediabetes: a cohort study

At a glance: The STEP trials